<DOC>
	<DOCNO>NCT00413387</DOCNO>
	<brief_summary>The aim study compare efficacy tolerability fix combination beclomethasone/formoterol pMDI budesonide/formoterol dry powder via Turbuhaler .</brief_summary>
	<brief_title>Efficacy Tolerability Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler® . ( Symbicort® )</brief_title>
	<detailed_description>Asthma chronic disease estimate affect 25 million people U.S. Europe ( i.e . approximately 10 % total population ) . Pharmacological therapy use treat reversible airway obstruction , inflammation hyper-reactivity . Medications include preventive treatment form antinflammatory/antiallergic agent ( i.e . glucocorticosteroids , leukotriene antagonist , cromolyn sodium ) reliever treatment , form bronchodilator ( i.e . β-adrenergic agonist , anticholinergic ) . In patient treat inhaled glucocorticosteroids whose asthma fully control , national international guideline recommend stepwise approach . Recent evidence-based clinical trial show addition LABA inhale glucocorticosteroids beneficial term asthma control increase dose corticosteroid alone . COMPARISONS : CHF 1535 ( BECLOMETHASONE DIPROPIONATE 100 µg+ FORMOTEROL 6 µg ) pMDI via HFA-134a compare SYMBICORT ( BUDESONIDE 160 µg + FORMOTEROL 4,5 µg ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Clinical diagnosis moderate severe persistent asthma least 6 month , accord GINA revise version 2002 guideline : Forced expiratory volume ( FEV1 ) peak expiratory flow rate ( PEFR ) &gt; 50 % &lt; 80 % predict normal ; Asthma adequately control current therapy , define presence daily asthma symptom &gt; week nighttime asthma symptom &gt; twice month , daily use shortacting β2agonists . These finding base recent medical history confirm 2week runin period . Treatment inhaled corticosteroid daily dose ≤ 1000 μg BDP equivalent . The daily dose inhale corticosteroid take visit 1 assess take account follow ratios dos different steroid : fluticasone propionate : BDP CFC = 1 : 2 ; budesonide : BDP CFC = 4 : 5 ; flunisolide : BDP CFC = 1 : 1 . The ratio inhale steroid irrespective formulation ( i.e . spray aerosol powder ) use . When BDP give new extrafine HFA134a formulation ( QVAR® , 3M Healthcare ) , ratio BDP CFC set 2 : 5 . Therefore , maximum allow daily dose inhaled corticosteroid study entry : budesonide 800 μg , fluticasone propionate 500 μg , flunisolide 1000 μg , BDP 1000 mcg , BDP HFA extrafine 400 μg . Positive response reversibility test screen visit , defined increase least 12 % ( , alternatively , 200mL ) baseline value measurement FEV1 30 minute follow 2 puff ( 2 x 100 µg ) inhale salbutamol administer via pMDI . The reversibility test avoid patient document positive response previous 6 month . A cooperative attitude ability train correctly use meter dose inhaler complete diary card . Written inform consent obtain . At end 2week runin period , presence daily asthma symptom ( least mild intensity ) nighttime asthma symptom ( least mild intensity ) &gt; week , well daily use relief salbutamol confirm review diary card runin Inability carry pulmonary function test ; Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) define National Heart Lung Blood Institute/World Health Organisation ( NHLBI/WHO ) Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline ( 30 ) ; History near fatal asthma ; Evidence severe asthma exacerbation symptomatic infection airways previous 8 week ; Three course oral corticosteroid hospitalisation due asthma previous 6 month ; Patients treat longacting β2agonists , anticholinergic antihistamines previous 2 week , topical intranasal corticosteroid leukotriene antagonist previous 4 week ; Patients change dose inhaled corticosteroid previous 4 week , treatment inhaled corticosteroid daily dose &gt; 1000 μg BDP equivalent ( except extrafine formulation , see inclusion criterion ) ; Current smoker recent ( less one year ) exsmokers , define smoke least 10 cigarettes/day ; History current evidence heart failure , coronary artery disease , myocardial infarction , severe hypertension , cardiac arrhythmia ; Diabetes mellitus ; Percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) previous six month ; Patients abnormal QTc interval value ECG test , define &gt; 450 msec male &gt; 470 msec female ; Other haemodynamic relevant rhythm disturbance ( include atrial flutter atrial fibrillation ventricular response , bradycardia ( ≤ 55 bpm ) , evidence atrialventricular ( AV ) block ECG 1st degree ; Clinically significant unstable concurrent disease : uncontrolled hyperthyroidism , significant hepatic impairment , poorly control pulmonary ( tuberculosis , active mycotic infection lung ) , gastrointestinal ( e.g . active peptic ulcer ) , neurological haematological autoimmune disease ; Cancer chronic disease prognosis &lt; 2 year ; Pregnant lactate female female risk pregnancy , i.e . demonstrate adequate contraception ( i.e . barrier method , intrauterine device , hormonal treatment sterilization ) . A pregnancy test carry woman fertile age . History alcohol drug abuse ; Patients treat monoamine oxidase inhibitor , tricyclic antidepressant betablockers regular use ; Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient ; Patients unlikely comply protocol unable understand nature , scope possible consequence study ; Patients receive investigational new drug within last 12 week ; Patients previously enrol study ; At end runin period , patient admit treatment period case increase PEFR ( L/sec ) measure clinic end runin period &gt; 15 % respect value measure start runin period ; Patients asthma exacerbation runin period also exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Combinations</keyword>
	<keyword>Inhaled therapy</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Long act bronchodilator</keyword>
	<keyword>Beclomethasone</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Budesonide</keyword>
</DOC>